As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline.  | As obesity ...

Replicate Bioscience will partner with Novo Nordisk to develop treatments using self-replicating RNA technology for obesity, type 2 diabetes and other cardiometabolic diseases, the privately held ...

Novo Nordisk agreed to collaborate with Replicate Biosciences to develop potential new treatments for obesity, type 2 diabetes and other cardiometabolic diseases, as it grapples with mounting ...

Novo Nordisk has turned to Replicate Bioscience’s RNA drug platform in a lucrative research collaboration, marking its latest ...

The agreement provides research funding for Replicate and up to $550M in payments to develop medicines for diseases including obesity and diabetes.

Novo Nordisk has brought on other cardiometabolic collaborators this year, including United Laboratories International and Deep Apple Therapeutics.

Replicate Bioscience and Novo Nordisk announce a multi-year $550M collaboration to develop srRNA-based therapies for obesity.

Novo Nordisk will use Replicate's self-replicating RNA platform to develop drugs for obesity, type 2 diabetes, and other conditions.

Looking to expand its portfolio, Danish pharma major Novo Nordisk has entered into a multi-year collaboration with Replicate Bioscience, a clinical-stage company pioneering next-generation ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...